Background: Despite clinical guidelines discouraging the practice, it is well-documented that the concomitant use of benzodiazepines and opioid analgesics occurs regularly. Information on concomitant use of buprenorphine for medication-assisted treatment (MAT) of opioid use disorder (OUD) and benzodiazepines, however, is limited. Thus, we aimed to describe real-world drug dispensing patterns for the concomitant use of buprenorphine products approved for MAT and benzodiazepines.

Methods: We examined concomitant use of buprenorphine for MAT and benzodiazepines using the 2013 Prescription Behavior Surveillance System data from eight states. For prescription-level analysis, we estimated the proportion of concomitant buprenorphine and benzodiazepine prescriptions and the proportions of concomitant prescriptions prescribed by the same provider (co-prescribing) and dispensed by the same pharmacy (co-dispensing) for each state. For patient-level analysis, we calculated the proportion of patients with ≥1 buprenorphine therapy episode overlapping with a benzodiazepine episode, i.e., concomitant users, and the proportion of concomitant users who experienced co-prescribing or co-dispensing.

Results: In 2013, 1,925,072 prescriptions of buprenorphine products for MAT were dispensed to 190,907 patients in eight states. Approximately 1 in 8 buprenorphine prescriptions was used concomitantly with ≥1 benzodiazepine prescription(s). Co-prescribing proportions ranged from 22.2 to 64.6% across states, while co-dispensing proportions ranged from 54.7 to 91.0%. Approximately 17.7% of patients had >1 buprenorphine episode overlapping a benzodiazepine episode for ≥7 cumulative days' supply. Among these patients, 33.1-65.2% experienced co-prescribing, and 65.1-93.3% experienced co-dispensing.

Conclusions: The concomitant use of buprenorphine for MAT and benzodiazepines occurs frequently, with variations by state in co-prescribing and co-dispensing.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978454PMC
http://dx.doi.org/10.1016/j.drugalcdep.2018.02.019DOI Listing

Publication Analysis

Top Keywords

concomitant buprenorphine
24
concomitant
10
buprenorphine
9
buprenorphine medication-assisted
8
medication-assisted treatment
8
opioid disorder
8
prescription behavior
8
behavior surveillance
8
surveillance system
8
buprenorphine products
8

Similar Publications

Is the Use of a Buprenorphine Transdermal Patch More Effective Than Oral Medications for Postoperative Analgesia After Arthroscopic Rotator Cuff Repair? A Randomized Clinical Trial.

Clin Orthop Relat Res

November 2024

Division of Sports Medicine and Adult Reconstructive Surgery, Department of Orthopedic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, PR China.

Article Synopsis
  • The study investigates whether transdermal buprenorphine patches provide better pain relief and shoulder function recovery compared to a regimen of oral tramadol and celecoxib in patients post-arthroscopic rotator cuff repair.!*
  • It was a randomized controlled trial including patients with specific eligibility criteria, and 64% of assessed patients were eligible for the study, leading to two groups: one receiving oral medication and the other using buprenorphine patches.!*
  • The research aims to measure pain relief, recovery of shoulder function, and the frequency of side effects between the two analgesic approaches to determine the effectiveness of buprenorphine patches in postoperative pain management.!*
View Article and Find Full Text PDF

Background: There is a great deal of confusion associated with conversion from CII opioid to buprenorphine products. The data presented supports that patients can be converted from high dose opioid medication to buprenorphine products safely and effectively. This presentation will provide a road map to help guide practitioners who are interested in applying this to their clinical practice.

View Article and Find Full Text PDF
Article Synopsis
  • Buprenorphine (BPN) is commonly used for pain relief in children, but research on how it works in young patients is limited.
  • The study aimed to understand how factors like age, gender, weight, height, BMI, and other medications impact the pharmacokinetics of BPN after intravenous administration in children aged 2-10 years undergoing surgery.
  • Results showed that age affects the drug's clearance and volume distribution, females experience different clearance rates than males, and taking BPN with other drugs like fentanyl and dexamethasone can reduce its clearance.
View Article and Find Full Text PDF

Introduction: Although psychoactive medicines (PMed) are needed in several psychiatric conditions, their use and misuse bear risks. We aimed at estimating the prevalence of PMed use and misuse.

Methods: Data on all PMed prescribed in 2017 and dispensed in community pharmacies of the Lisbon and Tagus Valley region of Portugal (ARSLVT) were extracted from ARSLVT medicines' dispensing database.

View Article and Find Full Text PDF

We studied opioid agonist treatment (OAT) status before buprenorphine-related death in Finland, where buprenorphine is the principal OAT medicine and also the most misused opioid, through a retrospective population-based study using medico-legal cause-of-death investigation and OAT patient records. The study included all death cases (N = 570) between 2018 and 2020 with a buprenorphine or norbuprenorphine finding in post-mortem toxicology and with known drug misuse history or concomitant findings of illicit drugs. Of the deceased, 10% had received OAT in the year before death.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!